Cover Image
市場調查報告書

法布瑞氏症的全球市場

Global Fabry Disease Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 318295
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
法布瑞氏症的全球市場 Global Fabry Disease Market 2015-2019
出版日期: 2014年11月05日 內容資訊: 英文 80 Pages
簡介

所謂法布瑞氏症,是溶小體內積蓄過多globotriaosylceramide的遺傳性溶小體儲積症,由於α半乳糖苷酶缺損引起倦怠感、血管角化瘤、耳鳴、腎功能障礙、心臟疾病、神經系統的疾病等症狀的病。全球法布瑞氏症市場,預計從2014年到2019年的期間年複合成長率成長18.08%。

本報告提供全球法布瑞氏症市場相關調查分析、市場概要、市場區隔考察、各地區考察、推動市場的要素與課題、主要企業等相關彙整。

第1章 摘要整理

第2章 簡稱一覽

第3章 報告的範圍

  • 市場概要
  • 商品一覽

第4章 市場調查的方法

  • 市場調查的流程
  • 調查方法

第5章 疾病概要

  • 溶小體儲積症
  • 法布瑞氏症

第6章 簡介

第7章 市場概要

  • 市場概要
  • 市場規模與預測
  • 全球法布瑞氏症市場過去分析
  • 波特的五力分析

第8章 市場區隔:各藥物製造所使用的細胞株

第9章 各地區市場區隔

第10章 購買標準

第11章 市場成長的促進要素

第12章 促進要素與其影響

第13章 市場課題

第14章 促進要素與課題的影子

第15章 市場趨勢

第16章 趨勢與其影響

第17章 供應商狀況

  • 競爭模式
  • 市場佔有率分析
  • 其他主要供應商

第18章 開發平台分析

  • 開發平台候補的臨床試驗分析

第19章 法布瑞氏症登記資料

第20章 主要供應商分析

  • Genzyme
  • Shire

第21章 本系列的其他報告

目錄
Product Code: IRTNTR4578

About Fabry Disease

Fabry disease is an inheritable lysosomal storage disease characterized by the excessive accumulation of globotriaosylceramide (GL-3) in lysosomes. It results from a deficiency of a-Gal and can result in symptoms such as fatigue, angiokeratoma, tinnitus, kidney failure, heart disorders, and nervous system problems. Fabry disease results from mutations in the galactosidase (GLA) gene, resulting in decreased activity or complete absence of a-Gal. Fabry disease resulting from the decreased activity of the enzyme is called later-onset Fabry disease. This form of the disease can effect both males and females. The symptoms of this disease typically appear during adulthood and usually focus on a single organ. Fabry disease resulting from the complete absence of a-Gal results in a more severe form called classic Fabry disease. The classic form of the disease usually affects males. The disease symptoms usually starts in adolescence and include clouded eye lenses, skin lesions, pain, and reduced sweating. If untreated, the disease can lead to cardiac dysfunction, renal failure or stroke, often resulting in death during fourth or fifth decade of life.

TechNavio's analysts forecast the Global Fabry Disease market to grow at a CAGR of 18.08 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Fabry Disease market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various innovator drugs available in the market for the treatment of fabry disease.

TechNavio's report, the Global Fabry Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Fabry Disease market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Genzyme
  • Shire

Other Prominent Vendors

  • Amicus Therapeutics
  • Green Cross Corporation
  • ISU Abxis
  • JCR Pharmaceuticals
  • Protalix Biotherapeutics

Market Driver

  • Special Provisions for Orphan Drugs
  • For a full, detailed list, view our report

Market Challenge

  • Limited Patient Population
  • For a full, detailed list, view our report

Market Trend

  • Regulatory Assistance in Emerging Countries
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

  • 05.1. Lysosomal Storage Disorders
  • 05.2. Fabry Disease
    • 05.2.1. Etiology and Pathophysiology
    • 05.2.2. Signs and Symptoms
    • 05.2.3. Epidemiology
    • 05.2.4. Inheritance Pattern

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Historical Analysis of Global Fabry Disease market
  • 07.4. Five Forces Analysis

08. Market Segmentation by Cell Line Used for Manufacturing the Drug

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2014
  • 17.3. Other Prominent Vendors and Future Vendors

18. Pipeline Analysis

  • 18.1. Clinical Trial Analysis of Pipeline Candidates
    • 18.1.1. AT1001
    • 18.1.2. GZ402671
    • 18.1.3. PRX-102

19. Fabry Registry

20. Key Vendor Analysis

  • 20.1. Genzyme
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Product Segmentation by Revenue 2013
    • 20.1.4. Product Segmentation by Revenue 2012 and 2013
    • 20.1.5. Geographical Segmentation
    • 20.1.6. Business Strategy
    • 20.1.7. Recent Developments
    • 20.1.8. SWOT Analysis
  • 20.2. Shire
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Geographical Segmentation by Revenue 2013
    • 20.2.4. Business Strategy
    • 20.2.5. Recent Developments
    • 20.2.6. SWOT Analysis

21. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Classification of Lysosomal Storage Diseases
  • Exhibit 3: Difference between Normal Cell and Fabry Disease Cell
  • Exhibit 4: Fabry Disease Symptoms by Age
  • Exhibit 5: Enzymatic Activity of α-GAL
  • Exhibit 6: Global Lysosomal Storage Diseases Market 2014-2019 (US$ billion)
  • Exhibit 7: Percentage Share of Fabry Disease in Global Lysosomal Storage Diseases Market 2014
  • Exhibit 8: Percentage Share of Fabry Disease in Global Lysosomal Storage Diseases Market 2014 and 2019
  • Exhibit 9: Global Fabry Disease Market 2014-2019 (US$ million)
  • Exhibit 10: Global Fabry Disease Market 2004-2014 (US$ million)
  • Exhibit 11: Global Fabry Disease Market Segmentation by Cell Line Used for Manufacturing the Drug
  • Exhibit 12: Market Share of Global Fabry Disease Market Segments 2014
  • Exhibit 13: Global Fabry Disease Market Segmentation by Drugs 2004-2014 (US$ million)
  • Exhibit 14: Sales of Fabry Disease Drugs 2004-2014 (US$ million)
  • Exhibit 15: Global Fabry Disease Market Segmentation by Drugs 2004-2014
  • Exhibit 17: Global Fabry Disease Market Segmentation by Geography 2014
  • Exhibit 18: Global Fabry Disease Market Share Analysis 2014
  • Exhibit 19: Key Event Timeline for Fabrazyme
  • Exhibit 20: Revenue of Fabrazyme 2004 - 2014(H1) (US$ million)
  • Exhibit 21: Impact of Lowered Dose of Fabrazyme by Country
  • Exhibit 22: Key Event Timeline for Replagal
  • Exhibit 23: Revenue of Replagal 2004 - 2014(H1) (US$ million)
  • Exhibit 24: Key Active Patents for Replagal
  • Exhibit 25: Clinical Trial Locations for AT1001
  • Exhibit 26: List of Clinical Trial Locations for AT1001
  • Exhibit 27: AT1001 Phase III Trial Locations
  • Exhibit 28: List of AT1001 Phase III Trial Locations
  • Exhibit 29: GZ402671 Phase II Trial Locations
  • Exhibit 30: List of GZ402671 Phase II Trial Locations
  • Exhibit 31: PRX-102 Phase 1/II Trial Locations
  • Exhibit 32: List of PRX-102 Phase 1/II Trial Locations
  • Exhibit 33: Enrolment Statistics for Fabry Registry
  • Exhibit 34: Enrolment Statistics for Fabry Registry by Geography 2012
  • Exhibit 35: Genzyme: Product Segmentation by Revenue 2013
  • Exhibit 36: Genzyme: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 37: Genzyme: Geographical Segmentation
  • Exhibit 38: Shire: Geographical Segmentation by Revenue 2013
Back to Top